Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 32,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo-Control Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarker Assessment of Glutamatergic Target Engagement

NCT02134951
View directory record Official record
Conditions
Healthy Controls
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 21, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Prednisone In the Treatment of Ocular Myasthenia

NCT00995722
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Michael Benatar
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

NCT02192931
View directory record Official record
Conditions
Depression, Dual Diagnosis, Drug Addiction
Interventions
Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Placebo (blinded), LX9211 (blinded)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

NCT01439854
View directory record Official record
Conditions
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

NCT02460094
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 21, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional Results available

Methylphenidate for Cancer-Related Fatigue

NCT01164956
View directory record Official record
Conditions
Cancer
Interventions
methylphenidate, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
7 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 21, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

NCT05992922
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle)
Drug
Lead sponsor
Iacta Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Misoprostol Versus Dilapan-S for Cervical Preparation

NCT00835731
View directory record Official record
Conditions
Cervical Ripening
Interventions
misoprostol, Dilapan-S, vitamin B-12
Drug · Device
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06173531
View directory record Official record
Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions
Carbetocin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 30 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01122602
View directory record Official record
Conditions
Drugs, Investigational
Interventions
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036), Acetylsalicyclic acid (Aspirin, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422
View directory record Official record
Conditions
Cold Agglutinin Disease
Interventions
sutimlimab (BIVV009), placebo
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

NCT01507753
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 21, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

NCT06444451
View directory record Official record
Conditions
Alopecia Areata
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

NCT00812929
View directory record Official record
Conditions
Asthma
Interventions
Placebo, GSK2190915
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT02130531
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Interventions
Emixustat HCl Tablet, Placebo Tablet
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 21, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 21, 2026, 4:27 AM EDT
Completed No phase listed Observational

LENS - Long-term Eltrombopag Observational Study

NCT00643929
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers

NCT02355002
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

NCT00984802
View directory record Official record
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Study of ALS-008176 in Infants Hospitalized With RSV

NCT02202356
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

NCT00115622
View directory record Official record
Conditions
Hayfever, Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Interventions
fluticasone furoate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 21, 2026, 4:27 AM EDT